HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

glutamyl-glutamic acid (Glu-Glu)

RN given for (L,L)-isomer
Also Known As:
Glu-Glu; dipotassium glutamyl-glutamate
Networked: 47 relevant articles (0 outcomes, 4 trials/studies)

Bio-Agent Context: Research Results

Experts

1. Tajima, Kazuo: 3 articles (07/2013 - 03/2002)
2. Matsuo, Keitaro: 3 articles (07/2013 - 03/2002)
3. Chen, Bo: 2 articles (07/2015 - 04/2013)
4. Oze, Isao: 2 articles (07/2013 - 08/2010)
5. Yatabe, Yasushi: 2 articles (07/2013 - 08/2010)
6. Hosono, Satoyo: 2 articles (07/2013 - 08/2010)
7. Ito, Hidemi: 2 articles (07/2013 - 08/2010)
8. Tanaka, Hideo: 2 articles (07/2013 - 08/2010)
9. Watanabe, Miki: 2 articles (07/2013 - 08/2010)
10. Zhang, Jia-Wei: 1 article (07/2015)

Related Diseases

1. Breast Neoplasms (Breast Cancer)
04/01/2013 - "Meta-analysis of total studies showed that the NBS1 Glu185Gln variant carriers were not susceptible to breast cancer (ORGln vs. Glu = 1.05, 95 % CI 0.80-1.39, P OR = 0.719; OR Gln/Gln vs. Glu/Glu = 0.82, 95 % CI 0.62-1.08, P OR = 0.154; OR Glu/Gln vs. Glu/Glu = 1.00, 95 % CI 0.90-1.13, P OR = 0.939; ORGln/Gln + Glu/Gln vs. Glu/Glu = 0.96, 95 % CI 0.83-1.11, P OR = 0.551; ORGln/Gln vs. Glu/Glu + Glu/Gln = 0.84, 95 % CI 0.67-1.05, P OR = 0.134). "
09/01/2010 - "The Malay, Chinese and Indian women who were Glu/Glu homozygotes (P= 0.419, 0.093, 0.367), Ala/Glu heterozygotes (P= 0.648, 0.182, 0.402) and carriers of Glu allele (P= 0.402, 0.079, 0.349), respectively, were not associated with breast cancer risk. "
04/01/2013 - "Overall, no significant associations were found between MTHFR Glu429Ala polymorphism and breast cancer risk when all studies were pooled into the meta-analysis (Glu/Glu vs Ala/Ala: OR = 0.891, 95 % CI = 0.782-1.015; Glu/Ala vs Ala/Ala: OR = 0.874, 95 % CI = 0.760-1.006; dominant model: OR = 0.885, 95 % CI = 0.775-1.012; and recessive model: OR = 0.989, 95 % CI = 0.931-1.051). "
04/01/2013 - "In the subgroup analysis by ethnicity, significantly elevated breast cancer risk was associated with Glu/Glu variant genotype in homozygote comparison and recessive genetic model (Glu/Glu vs Ala/Ala: OR = 0.78, 95 % CI = 0.63-0.97; Glu/Glu vs Glu/Ala: OR = 0.92, 95 % CI = 0.85-0.99; recessive model: OR = 0.91, 95 % CI = 0.85-0.97), while no significant associations were found for all comparison models in other ethnicity populations. "
2. Asthma (Bronchial Asthma)
3. Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome)
4. Neoplasms (Cancer)
5. Prostatic Neoplasms (Prostate Cancer)

Related Drugs and Biologics

1. Carbon Monoxide
2. Plasminogen Activators (Plasminogen Activator)
3. Tissue Plasminogen Activator (Alteplase)
4. glutamylalanine
5. alanylalanine (Ala-Ala)
6. lysyllysine (Lys-Lys)
7. aspartyl-aspartic acid (Asp-Asp)
8. aspartylglutamate
9. arginylarginine (Arg-Arg)
10. gamma-glutamylaspartic acid